The Problem
Today's AI systems make high-stakes decisions--across global security, finance, medicine, and more--without internal deliberation or ethical transparency. These opaque decision paths undermine public trust, expose organizations to regulatory risk, and increase the likelihood of harmful, unintended outcomes.
TransAI is an early stage start-up, building the first governance-layer infrastructure for AI designed to deliver transparent, traceable rationals for every decision. We target a specific B2B SaaS vertical: AI governance in high-stakes, compliance-heavy sectors such as healthcare, biotech, foreign policy, and finance. Our platform integrates directly into internal decision-making and advisory workflows, helping organizations manage algorithmic bias, auditability, and regulatory oversight--without micromanagement.
Our Solution
TransAI introduces a patent pending architecture including a deliberation engine that takes account of diverse cognitive and ethical perspectives; a petition and arbitration interface for human oversight at key junctures; a traceability layer for audit-ready decision histories; a dual track deployment with AI models based on proprietary deliberative committees of real historical personas or fully synthetic constructs.
Differentiators
Unlike other AI governance frameworks that rely on static policies, post-hoc explainability tools, or external oversight panels, TransAI embeds governance within the AI itself--through internal deliberation, cognitive maturation, and structured ethical memory. This allows decisions to be explained, audited and challenged from within, offering real-time transparency and accountability not available in conventional black-box systems.
Who We Are
Founder and CEO: Charles DeLisi, Dean emeritus of Boston University's College of Engineering, is a pioneer in computational and mathematical biology and widely recognized as the Father of the Human Genome Project. Charles also initiated its ethical, legal and social implications program, now a global model for scientific foresight.
Board of Advisors:
Sorin Alexe, founder and managing member QML Alpha, LLC, has more than 2 decades of hands-on experience developing and adapting a wide variety of machine learning methods.
Dileep Bhattacharya is Founder of DeNovo Analytics, a company that focuses on adaptive intelligence platforms. Prior to DeNovo, he held leadership positions with the IBM Systems Technology Group developing products in analytics, AI and supercomputing.
Dustin Holloway is VP and Global Head of Responsible Innovation at Sanofi Pharmaceuticals. He has held various AI related positions including Director and Global Lead for AI and Technology ethics at Takeda, and Deputy Director of Computational Immunology and System Biology at Sanofi Pasteur. Dustin has a PhD in Systems Biology and AI from Boston University and MPH from Harvard.
Mark Kon is Professor of Mathematic and Statistics at Boston University. His research includes Quantum probability and information, machine and statistical learning and financial portfolio analysis. Mark obtained his bachelor's degrees in mathematics, physics and psychology from Cornell University and a PhD in applied mathematics from MIT.
Zhiping Wang is LiWeibo Professor of Biomedical Research and founding Chair of the Dept. of Genomics and Computational Biology at University of Massachusetts School of Medicine. She is internationally recognized for adapting and using machine learning and data science to the understanding of complex processes.
Peter Wright advises on business strategy and AI. He is Founder and CEO of Intro-act Inc., an AI platform matching executives with institutional investors. His career background includes roles as an analyst at CIBC World Markets and at Fidelity Investments where he was rated #1 Technology Analyst by Institutional Investor two years in a row. Peter holds a degree in Economics from the Wharton School at the University of Pennsylvania.
Get in Touch
Contact us for detailed information on how TransAI can enhance your projects.